港股異動丨沛嘉醫療-B(9996.HK)急漲超10% 與JenaValve訂立產品許可協議
格隆匯1月18日丨沛嘉醫療-B(9996.HK)快速拉昇漲10.45%,報12.68港元,總市值85億港元。近日,公司宣佈與JenaValve簽署獨佔許可協議,JenaValve將向公司授予其專有開發的適用於主動脈瓣反流疾病的經導管主動脈瓣置換(TAVR)產品的獨佔許可,沛嘉醫療有權在大中華區製造、開發和商業化該產品。華創證券指出,Trilogy產品導入後,公司將補齊TAVR適應症佈局上最後一塊拼圖。公司銷售團隊在推進產品商業化上十分高效,新產品商業化也值得期待。維持“推薦”評級,目標價47港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.